

Helsinki, 20 January 2021

**Addressees**

Registrants of JS\_231-185-8 listed in the last Appendix of this decision

**Date of submission of the dossier subject of a decision**

22/05/2018

**Registered substance subject to this decision, hereafter 'the Substance'**

Substance name: Dimethyl (p-methoxybenzylidene)malonate

EC number: 231-185-8

CAS number: 7443-25-6

**Decision number:** [Please refer to the REACH-IT message which delivered this communication (in format TPE-D-XXXXXXXXXX-XX-XX/F)]**DECISION ON TESTING PROPOSAL(S)**

Based on Article 40 of Regulation (EC) No 1907/2006 (REACH), you must submit the information listed below by **27 January 2022**.

The requested information must be generated using the Substance unless otherwise specified.

**A. Information required from the Registrants subject to Annex VIII of REACH**

1. In vivo mammalian erythrocyte micronucleus test (triggered by Annex VIII, Section 8.4., column 2; test method: OECD TG 474) in mice or rats, oral route;

Reasons for the request(s) are explained in the following appendix:

- Appendix entitled "Reasons to request information required under Annex VIII of REACH".

**Information required depends on your tonnage band**

You must provide the information listed above for all REACH Annexes applicable to you, and in accordance with Articles 10(a) and 12(1) of REACH:

- the information specified in Annexes VII and VIII to REACH, for registration at 10-100 tpa.

**How to comply with your information requirements**

To comply with your information requirements you must submit the information requested by this decision in an updated registration dossier by the deadline indicated above. You must also update the chemical safety report, where relevant, including any changes to classification and labelling, based on the newly generated information.

You must follow the general testing and reporting requirements provided under the Appendix entitled "Requirements to fulfil when conducting and reporting new tests for REACH purposes". For references used in this decision, please consult the Appendix entitled "List of references".

**Appeal**

This decision can be appealed to the Board of Appeal of ECHA within three months of its notification. An appeal, together with the grounds thereof, has to be submitted to ECHA in writing. An appeal has suspensive effect and is subject to a fee. Further details are described under: <http://echa.europa.eu/regulations/appeals>.

Approved<sup>1</sup> under the authority of Christel Schilliger-Musset, Director of Hazard Assessment

---

<sup>1</sup> As this is an electronic document, it is not physically signed. This communication has been approved according to ECHA's internal decision-approval process.

**Appendix A: Reasons to request information required under Annex VIII of REACH**

This decision is based on the examination of the testing proposals you submitted.

**1. In vivo mammalian erythrocyte micronucleus test**

Under Annex VIII Section 8.4., column 2 of REACH, the performance of an appropriate *in vivo* somatic cell genotoxicity study must be considered if there is a positive result in any of the *in vitro* genotoxicity studies in Annex VII or VIII.

Your dossier contains positive results for an *in vitro* cytogenicity test which raises the concern for chromosomal aberrations. Moreover, no data from an *in vivo* somatic cell genotoxicity study is available in the dossier.

Therefore, you submitted a testing proposal for an *in vivo* mammalian erythrocyte micronucleus test to be performed with the Substance.

ECHA requested your considerations for alternative methods to fulfil the information requirement for Genetic toxicity *in vivo*. ECHA notes that you provided your considerations concluding that there were no alternative methods which could be used to adapt the information requirement(s) for which testing is proposed. ECHA has taken these considerations into account.

ECHA agrees that an appropriate *in vivo* follow up genotoxicity study is necessary to address the concern identified *in vitro*.

*i. Test selection*

ECHA notes that the proposed test is appropriate to investigate effects on chromosomal aberrations *in vivo*<sup>2</sup>.

According to the ECHA Guidance Chapter R.7a<sup>3</sup>, the mammalian erythrocyte micronucleus test ("MN test", OECD TG 474) is suitable to follow-up a positive *in vitro* result on chromosomal aberration if the Substance or its metabolite(s) will reach the target tissue.

*ii. Test design*

You proposed testing in mice. You proposed testing by the oral route.

According to the test method OECD TG 474, the test must be performed in mice or rats. Having considered the anticipated routes of human exposure and the need for adequate exposure of the target tissue(s) performance of the test by the oral route is appropriate.

Regarding the exposure of the target tissue, the applicable test guideline (OECD TG 474) states "If there is evidence that the test substance(s), or its metabolite(s), will not reach the target tissue, it may not be appropriate to use this test". Additionally, a negative test result can be considered reliable if "Bone marrow exposure to the test substance(s) occurred". Accordingly, if the Substance is negative in this test, but it is not possible to demonstrate that bone marrow exposure to the Substance occurred, then ECHA will consider any remaining uncertainty concerning the mutagenic potential of the Substance and whether to request any further information.

<sup>2</sup> ECHA Guidance R.7a, Section R.7.7.6.3. and Figure R.7.7-1

<sup>3</sup> ECHA Guidance Chapter R.7a, Section R.7.7.6.3

*iii. Outcome*

Under Article 40(3)(a) of REACH, you are requested to carry out the proposed test with the Substance.

## **Appendix B: Requirements to fulfil when conducting and reporting new tests for REACH purposes**

### **A. Test methods, GLP requirements and reporting**

1. Under Article 13(3) of REACH, all new data generated as a result of this decision must be conducted according to the test methods laid down in a European Commission Regulation or to international test methods recognised by the Commission or ECHA as being appropriate.
2. Under Article 13(4) of REACH, ecotoxicological and toxicological tests and analyses must be carried out according to the GLP principles (Directive 2004/10/EC) or other international standards recognised by the Commission or ECHA.
3. Under Article 10(a)(vi) and (vii) of REACH, all new data generated as a result of this decision must be reported as study summaries, or as robust study summaries, if required under Annex I of REACH. See ECHA Practical Guide on How to report robust study summaries<sup>4</sup>.

### **B. Test material**

Before generating new data, you must agree within the joint submission on the chemical composition of the material to be tested (Test material) which must be relevant for all the registrants of the Substance.

#### **1. Selection of the Test material(s)**

The Test material used to generate the new data must be selected taking into account the following:

- the variation in compositions reported by all members of the joint submission,
- the boundary composition(s) of the Substance,
- the impact of each constituent/ impurity on the test results for the endpoint to be assessed. For example, if a constituent/ impurity of the Substance is known to have an impact on (eco)toxicity, the selected Test material must contain that constituent/ impurity.

#### **2. Information on the Test material needed in the updated dossier**

- You must report the composition of the Test material selected for each study, under the "Test material information" section, for each respective endpoint study record in IUCLID.
- The reported composition must include all constituents of each Test material and their concentration values and other parameters relevant for the property to be tested.

This information is needed to assess whether the Test material is relevant for the Substance and whether it is suitable for use by all members of the joint submission.

Technical instructions on how to report the above is available in the manual on How to prepare registration and PPORD dossiers<sup>5</sup>.

<sup>4</sup> <https://echa.europa.eu/practical-guides>

<sup>5</sup> <https://echa.europa.eu/manuals>

**Appendix C: Procedure**

ECHA started the testing proposal evaluation in accordance with Article 40(1) on 1 June 2018,

ECHA held a third party consultation for the testing proposal(s) from 23 March 2020 until 7 May 2020. ECHA did not receive information from third parties.

ECHA notified you of the draft decision and invited you to provide comments.

ECHA did not receive any comments within the notification period.

ECHA notified the draft decision to the competent authorities of the Member States for proposals for amendment.

As no amendments were proposed, ECHA adopted the decision under Article 51(3) of REACH.

**Appendix D: List of references - ECHA Guidance<sup>6</sup> and other supporting documents**Evaluation of available information

Guidance on information requirements and chemical safety assessment, Chapter R.4 (version 1.1., December 2011), referred to as ECHA Guidance R.4 where relevant.

QSARs, read-across and grouping

Guidance on information requirements and chemical safety assessment, Chapter R.6 (version 1.0, May 2008), referred to as ECHA Guidance R.6 where relevant.

Read-across assessment framework (RAAF, March 2017)<sup>7</sup>

RAAF - considerations on multi-constituent substances and UVCBs (RAAF UVCB, March 2017)<sup>8</sup> **Error! Bookmark not defined.**

Physical-chemical properties

Guidance on information requirements and chemical safety assessment, Chapter R.7a (version 6.0, July 2017), referred to as ECHA Guidance R.7a in this decision.

Toxicology

Guidance on information requirements and chemical safety assessment, Chapter R.7a (version 6.0, July 2017), referred to as ECHA Guidance R.7a in this decision.

Guidance on information requirements and chemical safety assessment, Chapter R.7c (version 3.0, June 2017), referred to as ECHA Guidance R.7c in this decision.

Environmental toxicology and fate

Guidance on information requirements and chemical safety assessment, Chapter R.7a (version 6.0, July 2017), referred to as ECHA Guidance R.7a in this decision.

Guidance on information requirements and chemical safety assessment, Chapter R.7b (version 4.0, June 2017), referred to as ECHA Guidance R.7b in this decision.

Guidance on information requirements and chemical safety assessment, Chapter R.7c (version 3.0, June 2017), referred to as ECHA Guidance R.7c in this decision.

PBT assessment

Guidance on information requirements and chemical safety assessment, Chapter R.11 (version 3.0, June 2017), referred to as ECHA Guidance R.11 in this decision.

Guidance on information requirements and chemical safety assessment, Chapter R.16 (version 3.0, February 2016), referred to as ECHA Guidance R.16 in this decision.

Data sharing

Guidance on data-sharing (version 3.1, January 2017), referred to as ECHA Guidance on data sharing in this decision.

OECD Guidance documents<sup>8</sup>

<sup>6</sup> <https://echa.europa.eu/guidance-documents/guidance-on-information-requirements-and-chemical-safety-assessment>

<sup>7</sup> <https://echa.europa.eu/support/registration/how-to-avoid-unnecessary-testing-on-animals/grouping-of-substances-and-read-across>

<sup>8</sup> <http://www.oecd.org/chemicalsafety/testing/series-testing-assessment-publications-number.htm>

Guidance Document on aqueous-phase aquatic toxicity testing of difficult test chemicals – No 23, referred to as OECD GD 23.

Guidance document on transformation/dissolution of metals and metal compounds in aqueous media – No 29, referred to as OECD GD 29.

Guidance Document on Standardised Test Guidelines for Evaluating Chemicals for Endocrine Disruption – No 150, referred to as OECD GD 150.

Guidance Document supporting OECD test guideline 443 on the extended one-generation reproductive toxicity test – No 151, referred to as OECD GD 151.



**Appendix E: Addressees of this decision and the corresponding information requirements applicable to them**

You must provide the information requested in this decision for all REACH Annexes applicable to you.

<b>Registrant Name</b>	<b>Registration number</b>	<b>(Highest) Data requirements to be fulfilled</b>
[REDACTED]	[REDACTED]	[REDACTED]

Where applicable, the name of a third party representative (TPR) may be displayed in the list of recipients whereas ECHA will send the decision to the actual registrant.